Specificity of the Antibody Response to the Pneumococcal Polysaccharide and Conjugate Vaccines in Human Immunodeficiency Virus-Infected Adults

Clinical and Diagnostic Laboratory Immunology

Volumn 11, Issue 1, 2004, Pages 137-141

  Feikin, Daniel R ^a,e   Elie, Cheryl M ^a   Goetz, Matthew B ^c   Lennox, Jeffrey L ^b   Carlone, George M ^a   Romero Steiner, Sandra ^a   Holder, Patricia F ^a   O'Brien, William A ^d   Whitney, Cynthia G ^a   Butler, Jay C ^a,e   Breiman, Robert F ^a,f  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b EMORY UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^f ICDDR B Centre for Health and Population Research   (Bangladesh)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; PNEUMOCOCCUS POLYSACCHARIDE;

ADULT; ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; HAEMOPHILUS INFLUENZAE TYPE B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; LYMPHOCYTE COUNT; OPSONIZATION; PHAGOCYTOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROTYPE; VACCINATION; VIRUS LOAD;

ADULT; ANTIBODIES, BACTERIAL; ANTIBODY SPECIFICITY; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV INFECTIONS; HUMANS; IMMUNOGLOBULIN G; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE;

EID: 9144246124     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/CDLI.11.1.137-141.2004     Document Type: Article

References (27)

1. Ahmed, F., M. C. Steinhoff, M. C. Rodriguez-Barradas, R. G. Hamilton, D. M. Musher, and K. E. Nelson. 1999. Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: results from a randomized trial. J. Infect. Dis. 173:83-90.
2. Black, S., H. Shinefield, B. Fireman, E. Lewis, P. Ray, J. R. Hansen, L. Elvin, K. M. Ensor, J. Hackell, G. Siber, F. Malinoski, D. Madore, I. Chang, R. Kohberger, W. Watson, R. Austrian, and K. Edwards. 2000. Efficacy, safety, and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr. Infect. Dis. J. 19:187-195.
3. Black, S. B., H. R. Shinefield, S. Ling, J. Hansen, B. Fireman, D. Spring, J. Noyes, E. Lewis, P. Ray, J. Lee, and J. Hackell. 2002. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr. Infect. Dis. J. 21:810-815.
4. Breiman, R. F., D. W. Keller, M. A. Phelan, D. H. Sniadack, D. S. Stephens, D. Rimland, M. M. Farley, A. Schuchat, and A. L. Reingold. 2000. Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients. Arch. Intern. Med. 160:2633-2638.
5. Centers for Disease Control and Prevention. 1997. Prevention of pneumococcal disease. Morb. Mortal. Wkly. Rep. 46:1-24.
6. Concepcion, N. F., and C. E. Frasch. 2001. Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin. Diagn. Lab. Immunol. 8:266-272.
7. Coughlin, R. T., A. C. White, C. A. Anderson, G. M. Carlone, D. L. Klein, and J. Treanor. 1998. Characterization of pneumococcal specific antibodies in healthy unvaccinated adults. Vaccine 16:1761-1767.
8. Dworkin, M. S., J. W. Ward, D. L. Hanson, J. L. Jones, and J. E. Kaplan. 2001. Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination. Clin. Infect. Dis. 32:794-800.
9. Eskola, J., T. Kilpi, A. Palmu, J. Jokinen, J. Haapakoski, E. Herva, A. Takala, H. Kayhty, P. Karma, R. Kohberger, G. Siber, and P. H. Makela. 2001. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N. Engl. J. Med. 344:403-409.
10. Feikin, D. R., C. M. Elie, M. B. Goetz, J. L. Lennox, G. M. Carlone, S. Romero-Steiner, P. F. Holder, W. A. O'Brien, C. G. Whitney, J. C. Butler, and R. F. Breiman. 2001. Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults. Vaccine 20:545-553.
11. French, N., J. Nakiyingi, L. M. Carpenter, E. Lugada, C. Watera, K. Moi, M. Moore, D. Antvelink, D. Mulder, E. N. Janoff, J. Whitworth, and C. F. Gilks. 2000. 23-Valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet 355:2106-2111.
12. Gilks, C. F., S. A. Ojoo, J. C. Ojoo, R. J. Brindle, J. Paul, B. I. Batchelor, J. N. Kimari, R. Newnham, J. Bwayo, and F. A. Plummer. 1996. Invasive pneumococcal disease in a cohort of predominantly HIV-1 infected female sex-workers in Nairobi, Kenya. Lancet 347:718-723.
13. Glaser, J. B., S. Volpe, A. Aguirre, H. Simpkins, and G. Schiffman. 1991. Zidovudine improves response to pneumococcal vaccine among persons with AIDS and AIDS-related complex. J. Infect. Dis. 164:761-764.
14. Jacobson, D. L., J. A. McCutchan, P. L. Spechko, I. Abramson, R. S. Smith, A. Bartok, G. R. Boss, D. Durand, S. A. Bozzette, S. A. Spector, and D. D. Richman. 1991. The evolution of lymphadenopathy and hypergammaglobulinemia are evidence for early and sustained polyclonal B lymphocyte activation during human immunodeficiency virus infection. J. Infect. Dis. 163:240-246.
15. Janoff, E. N., J. M. Douglas, Jr., M. Gabriel, M. J. Blaser, A. J. Davidson, D. L. Cohn, and F. N. Judson. 1988. Class-specific antibody response to pneumococcal capsular polysaccharides in men infected with human immunodeficiency virus type 1. J. Infect. Dis. 158:983-990.
16. Jolliff, C. R., K. M. Cost, P. C. Stivrins, P. P. Grossman, C. R. Nolte, S. M. Franco, K. J. Fijan, L. L. Fletcher, and H. C. Shriner. 1982. Reference intervals for serum IgG, IgA, IgM, C3, and C4 as determined by rate nephelometry. Clin. Chem. 28:126-128.
17. Lane, H. C., J. M. Depper, W. C. Greene, G. Whalen, T. A. Waldmann, and A. S. Fauci. 1985. Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition. N. Engl. J. Med. 313:79-84.
18. Lane, H. C., H. Masur, L. C. Edgar, G. Whalen, A. H. Rook, and A. S. Fauci. 1983. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med. 309:453-458.
19. Nuorti, J., J. Butler, L. Gelling, J. L. Kool, A. L. Reingold, and D. J. Vugia. 2000. Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California. Ann. Intern. Med. 132:182-190.
20. Plikaytis, B. D., D. Goldblatt, C. E. Frasch, C. Blondeau, M. J. Bybel, G. S. Giebink, I. Jonsdottir, H. Kayhty, H. B. Konradsen, D. V. Madore, M. H. Nahm, C. A. Schulman, P. F. Holder, T. Lezhava, C. M. Elie, and G. M. Carlone. 2000. An analytical model applied to a multicenter pneumococcal enzyme-linked immunosorbent assay study. J. Clin. Microbiol. 38:2043-2050.
21. Rodriguez-Barradas, M. C., D. M. Musher, C. Lahart, C. Lacke, J. Groover, D. Watson, R. Baughn, T. Cate, and G. Crofoot. 1992. Antibody to capsular polysaccharides of Streptococcus pneumoniae after vaccination of human immunodeficiency virus-infected subjects with 23-valent pneumococcal vaccine. J. Infect. Dis. 165:553-556.
22. Romero-Steiner, S., D. Libutti, L. B. Pais, J. Dykes, P. Anderson, J. C. Whitin, H. L. Keyserling, and G. M. Carlone. 1997. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin. Diagn. Lab. Immunol. 4:415-422.
23. Romero-Steiner, S., D. Musher, and M. Cetron. 1999. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin. Infect. Dis. 29:281-288.
24. Soininen, A., G. van den Dobbelsteen, L. Oomen, and H. Kayhty. 2000. Are the enzyme immunoassays for antibodies to pneumococcal capsular polysaccharides serotype specific? Clin. Diagn. Lab. Immunol. 7:468-476.
25. Soininen, A., M. Karpala, S. Wahlman, H. Lehtonen, and H. Kayhty. 2002. Specificities and opsonophagocytic activities of antibodies to pneumococcal capsullar polysaccharides in sera of unimmunized young children. Clin. Diagn. Lab. Immunol. 9:1032-1038.
26. Steinhoff, M. C., B. S. Auerbach, K. E. Nelson, D. Vlahov, R. L. Becker, N. M. Graham, D. H. Schwartz, A. H. Lucas, and R. E. Chaisson. 1991. Antibody responses to Haemophilus influenzae type B vaccines in men with human immunodeficiency virus infection. N. Engl. J. Med. 325:1837-1842.
27. Yu, X., Y. Sun, C. Frasch, N. Concepcion, and M. H. Nahm. 1999. Pneumococcal capsular polysaccharide preparations may contain non-C-polysaccharide contaminants that are immunogenic. Clin. Diagn. Lab. Immunol. 6:519-524.